NCT00509041 · REGISTRY CONDITION SEARCH

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2016-08-11

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated malignant mesothelioma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

24 Week Progression Free Survival

→

outcome · POSTED

Number of Participants With Overall Tumor Response

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Progression Free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed malignant mesothelioma of any of the following subtypes: * Epithelial * Sarcomatoid * Mixed * Any site of origin of malignant mesothelioma allowed including, but not limited to, any of the following: * Pleura * Peritoneum * Pericardium * Tunica vaginalis * Pathology blocks or slides from a core surgical biopsy must be available * Not amenable to curative surgery * Measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques (CT scan , MRI, or x-ray) or as ≥ 10 mm with spiral CT scan * Patients with pleural rind only disease must have at least one level with one rind measurement ≥ 1.5 cm * Lesions that are considered nonmeasurable include the following: * Bone lesions * Leptomeningeal disease * Ascites * Pleural/pericardial effusion * Lymphangitis cutis/pulmonis * Abdominal masses that are not confirmed and followed by imaging techniques * Cystic lesions * Prior treatment with one and only one systemic chemotherapy regimen, which must have included pemetrexed disodium required * Treatment may have been with pemetrexed disodium alone or in combination with any other agent * No symptomatic pleural effusions, unless the patient undergoes a therapeutic thoracentesis * Patients with pleural effusions who have had a pleurodesis are eligible * No known brain metastases * May be registered on CALGB-150707 companion study PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Granulocytes ≥ 1,500/μL * Platelet count ≥ 100,000/μL * Total bilirubin ≤ 2 x upper limit of normal (ULN) * AST (SGOT) ≤ 2.5 x ULN * Creatinine clearance ≥ 60 mL/min * INR \< 1.5 * PTT \< 40 seconds * QTc \< 450 msec * Not pregnant or nursing * Fertile patients must use effective contraception * No significant cardiac disease, including any of the following: * New York Heart Association (NYHA) class III-IV congestive heart failure (CHF) * Unstable angina * Myocardial infarction or ventricular tachyarrhythmia within 6 months of study entry * Ejection fraction less than institutional normal (in patients with a history of CHF or currently with NYHA class I or II CHF) * Prolonged QTc \> 450 msec (Fridericia correction) * Major conduction abnormality, unless a cardiac pacemaker is present * Hypokalemia or hypomagnesemia that cannot be corrected * No history of significant bleeding disorder unrelated to cancer, including any of the following: * Congenital bleeding disorder (e.g., von Willebrand disease) * Acquired bleeding disorder within the past year (e.g., acquired anti-factor VIII antibodies) * Ongoing or recent (≤ 3 months) significant GI bleeding or hemoptysis * No requirement for supplemental oxygen (i.e., pulse oximetry \< 89% at rest) PRIOR CONCURRENT THERAPY: * At least 4 weeks since prior pemetrexed disodium-containing chemotherapy * At least 4 weeks since prior major surgery * At least 4 weeks since prior radiation therapy * Measurable disease must be outside the radiation port * Prior intracavitary cytotoxic or sclerosing therapy (including bleomycin) allowed * Intrapleural cytotoxic chemotherapy will not be considered systemic chemotherapy * At least 7 days since prior and no concurrent antithrombotic or anti-platelet agents, including any of the following: * Aspirin or aspirin-containing combinations * Clopidogrel * Dipyridamole * Tirofiban * Epoprostenol * Eptifibatide * Cilostazol * Abciximab * Ticlopidine * Warfarin * Low-dose warfarin for prophylaxis to prevent catheter thrombosis allowed * Heparin or low molecular weight heparin * Heparin for IV line flush allowed * At least 7 days since prior and no concurrent use of the following drugs: * Itraconazole * Ketoconazole (at doses \> 200 mg/day) * Miconazole * Voriconazole * Telithromycin * Primidone * Rifabutin * Rifampin * St. John's wort * Carbamazepine * Oxcarbazepine * Rifapentine * Phenobarbital * Phenytoin * Quinidine * Procainamide * Disopyramide * Amiodarone * Sotalol * Ibutilide * Dofetilide * Erythromycin * Clarithromycin * Chlorpromazine * Haloperidol * Mesoridazine * Thioridazine * Pimozide * Bepridil * Droperidol * Halofantrine * Levomethadyl * Sparfloxacin * No concurrent H2 blockers or proton pump inhibitors * No bisphosphonate therapy during the first 8 weeks of study treatment * No concurrent hormones or other chemotherapeutic agents except for steroids administered for dasatinib-related pleural effusion or hormones administered for non-disease-related conditions (e.g., insulin for diabetes) * No concurrent palliative radiation therapy
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Use of dasatinib in treatment of pts with previously treated malignant mesothelioma
intervention Names
Drug: dasatinib
label
Dasatinib
type
EXPERIMENTAL

interventions

arm Group Labels
Dasatinib
description
50 mg PO bid
name
dasatinib
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 46
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Percentage of participants who were alive and progression free at 24 weeks. The 24 week progression free survival, with 95% confidence interval, was estimated using the Kaplan Meier method.
measure
24 Week Progression Free Survival
time Frame
24 weeks

secondary Outcomes

description
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: * Complete Response (CR): disappearance of all target lesions; * Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; * Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; * Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs.
measure
Number of Participants With Overall Tumor Response
time Frame
Duration of study until progression (up to 3 years)
description
Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method.
measure
Overall Survival
time Frame
Time from registration to death (up to 3 years)
description
Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Progression free and alive patients were censored at the date of last follow-up. The median PFS with 95% CI was estimated using the Kaplan Meier method.
measure
Progression Free Survival
time Frame
Time from registration to progression or death (up to 3 years)

Full study description

brief Summary: RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated malignant mesothelioma.
detailed Description: OBJECTIVES: Primary * To determine the rate of progression-free survival (PFS) at 24 weeks (or 5.5 months) in patients with malignant mesothelioma treated with dasatinib. Secondary * To determine the response rate (partial response \[PR\] and complete response \[CR\]) in patients with malignant mesothelioma treated with dasatinib. * To determine the response duration in patients with malignant mesothelioma treated with dasatinib. * To describe the overall survival (OS) of patients with malignant mesothelioma treated with dasatinib. * To describe the toxicity profile of dasatinib in patients with malignant mesothelioma. * To determine whether the amount of expression of EphA2 and PDGFRβ, as measured by immunohistochemistry from tumor specimens, correlates with PFS in patients with malignant mesothelioma. * To determine whether plasma levels of VEGF and PDGFRβ, serum levels of CSF-1, and soluble mesothelin-related protein correlate with PFS in patients with malignant mesothelioma. * To determine whether inhibition of Src phosphorylation in PBMC correlates with PFS. * To assess inhibition of phosphorylation of Src, EphA2, and PDGFRβ in tumor tissue by dasatinib. OUTLINE: Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo tumor tissue and blood sample collection periodically for correlative studies. Tumor tissue samples are analyzed for EphA2 and PDGFRβ expression by immunohistochemistry. Tumor tissue samples may also be analyzed for phosphorylation of Src, EphA2, and PDGFRβ by western blot. Blood samples are analyzed for concentration of VEGF and PDGF by quantitative sandwich enzyme immunoassay technique; mesothelin-related protein level by Mesomark® assay; CSF-1 level by ELISA assay; and phosphorylation of Src by phospho-Src (pTyr418) human ELISA. After completion of study treatment, patients are followed at least every 2 months for 1 year, then every 4 months for 1 year, then every 6 months for 1 year.

Source references

references

citation
Dudek A, Pang H, Kratzke RA, et al.: CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). [Abstract] J Clin Oncol 28 (Suppl 15) A-7037, 2010.
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-08a2101cde490d910cfc
requested nct id
NCT00509041
primary nct id
NCT00509041
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
payload sha256
703a646474ba86505d824226f0775c4ec8f7b5a6a6da68528e278e9ee56149ac
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-08a2101cde490d910cfc
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00509041
occurrences
context exact
NCT00509041
end
11
exact text
NCT00509041
start
0
offset unit
unicode_code_points
query cond
Malignant Mesothelioma
query disease state id
ds-malignant-mesothelioma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
source json pointer
/studies/38/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
4869da50948255e02c6ae71a2001072f272b77ef5db600fedbf7c171c04d057d
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice